The estimated Net Worth of Raj Mehra is at least 761 千$ dollars as of 1 December 2023. Dr Mehra owns over 75,757 units of Seelos Therapeutics stock worth over 37,028$ and over the last 5 years he sold SEEL stock worth over 0$. In addition, he makes 724,234$ as Founder、 Chairman、 CEO & Pres at Seelos Therapeutics.
Sign up
Dr D SEEL stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Seelos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 75,757 units of SEEL stock worth 99,999$ on 1 December 2023.
The largest trade he's ever made was buying 133,333 units of Seelos Therapeutics stock on 13 February 2020 worth over 100,000$. On average, Dr trades about 30,640 units every 154 days since 2020. As of 1 December 2023 he still owns at least 185,142 units of Seelos Therapeutics stock.
You can see the complete history of Dr Mehra stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Raj Mehra J.D., Ph.D. biography
Dr. Raj Mehra J.D., Ph.D. is the Founder, Chairman, CEO & Pres at Seelos Therapeutics.
What is the salary of Dr D?
As the Founder、 Chairman、 CEO & Pres of Seelos Therapeutics, the total compensation of Dr D at Seelos Therapeutics is 724,234$. There are 1 executives at Seelos Therapeutics getting paid more, with Richard Pascoe having the highest compensation of 917,292$.
How old is Dr D?
Dr D is 61, he's been the Founder、 Chairman、 CEO & Pres of Seelos Therapeutics since . There are no older and 4 younger executives at Seelos Therapeutics.
What's Dr D's mailing address?
Raj's mailing address filed with the SEC is C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 2ND FLOOR, NEW YORK, NY, 10022.
Insiders trading at Seelos Therapeutics
Over the last 6 years, insiders at Seelos Therapeutics have traded over 0$ worth of Seelos Therapeutics stock and bought 409,757 units worth 387,856$ . The most active insiders traders include Brian Lian、Raj Mehra、Robin L Smith. On average, Seelos Therapeutics executives and independent directors trade stock every 231 days with the average trade being worth of 13,659$. The most recent stock trade was executed by Raj Mehra on 1 December 2023, trading 75,757 units of SEEL stock currently worth 99,999$.
What does Seelos Therapeutics do?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
What does Seelos Therapeutics's logo look like?
Complete history of Dr Mehra stock trades at Seelos Therapeutics
Seelos Therapeutics executives and stock owners
Seelos Therapeutics executives and other stock owners filed with the SEC include:
-
Richard Pascoe,
Director -
Dr. Raj Mehra J.D., Ph.D.,
Founder, Chairman, CEO & Pres -
Daniel O'Connor,
Director -
Brian Lian,
Director -
Judith Dunn,
Director -
Warren Wasiewski,
Chief Scientific Officer -
Raj Mehra,
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer -
Tim Whitaker M.D.,
Chief Medical Officer -
Gopal Krishna Ph.D.,
Head of Manufacturing & Technical Operations -
Anthony Marciano,
Chief Communications Officer -
Kimberly Farrand,
Sr. Director of Clinical Devel. & Operations -
Michael J. Golembiewski,
Chief Financial Officer -
Robin L Smith,
Director -
Michael Joseph Golembiewski,
Chief Financial Officer